Amgen, Otsuka and Simcere Pharmaceutical Group side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Amgen | Otsuka | Simcere Pharmaceutical Group |
|---|---|---|---|
| Phase 1 | Amgen: 8 of its 24 programs at phase 1
and 3 more — sign in to see them all | Otsuka: 12 of its 25 programs at phase 1
and 7 more — sign in to see them all | Simcere Pharmaceutical Group: 9 of its 16 programs at phase 1
and 4 more — sign in to see them all |
| Phase 2 | Amgen: 1 of its 24 programs at phase 2
| Otsuka: 2 of its 25 programs at phase 2
| Simcere Pharmaceutical Group: 1 of its 16 programs at phase 2
|
| Phase 3 | Amgen: 7 of its 24 programs at phase 3
and 2 more — sign in to see them all | Otsuka: 10 of its 25 programs at phase 3
and 5 more — sign in to see them all | Simcere Pharmaceutical Group: 5 of its 16 programs at phase 3
|
| Approved, new studies | Amgen: 8 of its 24 programs at approved, new studies
and 3 more — sign in to see them all | Otsuka: 1 of its 25 programs at approved, new studies
| Simcere Pharmaceutical Group: 1 of its 16 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen12 readouts · 3 phase 3 | · | Amgen, Dec ’26: 1 program whose next study reaches primary completion
| Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3
| Amgen, Feb ’27: 1 program whose next study reaches primary completion
| Amgen, Mar ’27: 1 program whose next study reaches primary completion
| Amgen, Apr ’27: 2 programs whose next study reaches primary completion
| Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | Amgen, Oct ’27: 1 program whose next study reaches primary completion
|
| Otsuka8 readouts · 3 phase 3 | · | Otsuka, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | Otsuka, Feb ’27: 1 program whose next study reaches primary completion
| Otsuka, Mar ’27: 1 program whose next study reaches primary completion
| · | Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3
| Otsuka, Jun ’27: 1 program whose next study reaches primary completion
| · | Otsuka, Aug ’27: 1 program whose next study reaches primary completion | · | · |
| Simcere Pharmaceutical Group2 readouts · 1 phase 3 | · | · | · | · | · | · | · | Simcere Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion
| Simcere Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · |
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Amgen
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 5
- xaluritamigphase 1 · Mar 2030 → Jul 2030 (+4 mo) · moved Nov 12 · NCT04221542
- tarlatamabphase 3 · Jul 2027 → Apr 2030 (+33 mo) · moved Nov 6 · NCT06211036
- tarlatamabphase 1 · Dec 2026 → Dec 2027 (+12 mo) · moved Nov 4 · NCT03319940
- tarlatamabphase 2 · May 2029 → Aug 2029 (+3 mo) · moved Oct 6 · NCT06745323
- blinatumomabphase 2 · Dec 2028 → Mar 2031 (+27 mo) · moved Oct 5 · NCT07134088
Otsuka
New programs 0
None
Reached a new phase 1
- VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Study stopped 1
- SEP-380135phase 1 · withdrawn Nov 19 · none of its studies left running“The trial was withdrawn prior to participant enrollment.” · NCT07455084
Primary completion later 3
- quabodepistatphase 3 · May 2027 → Sep 2028 (+16 mo) · moved Oct 26 · NCT07209761
- Tolvaptanphase 3 · Jul 2028 → Dec 2028 (+5 mo) · moved Oct 23 · NCT04782258
- SEP-380135phase 1 · Apr 2026 → Dec 2026 (+8 mo) · moved Oct 16 · NCT07455084
Where they overlap
Conditions where at least two of them have programs: 10 in all. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Amgen | Otsuka | Simcere Pharmaceutical Group |
|---|---|---|---|
| VEGFA | afliberceptrule | – | suvemcitugrule, SIM0689rule |
| PDE4A | apremilastrule | difamilastrule | – |
| PDE4B | apremilastrule | difamilastrule | – |
| PDE4C | apremilastrule | difamilastrule | – |
| PDE4D | apremilastrule | difamilastrule | – |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.